|
1
|
Langan RC, Gotsch PB, Krafczyk MA and
Skillinge DD: Ulcerative colitis: diagnosis and treatment. Am Fam
Physician. 76:1323–1330. 2007.PubMed/NCBI
|
|
2
|
Bamias G and Cominelli F:
Immunopathogenesis of inflammatory bowel disease: current concepts.
Curr Opin Gastroenterol. 23:365–369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Farrell RJ and Peppercorn MA: Ulcerative
colitis. Lancet. 359:331–340. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niess JH, Mönnikes H, Dignass AU, Klapp BF
and Arck PC: Review on the influence of stress on immune mediators,
neuro-peptides and hormones with relevance for inflammatory bowel
disease. Digestion. 65:131–140. 2002. View Article : Google Scholar
|
|
5
|
Sonnenberg A: Occupational distribution of
inflammatory bowel disease among German employees. Gut.
31:1037–1040. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Necefli A, Tulumoğlu B, Giriş M, et al:
The effect of melatonin on TNBS-induced colitis. Dig Dis Sci.
51:1538–1545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mazzon E, Esposito E, Crisafulli C, et al:
Melatonin modulates signal transduction pathways and apoptosis in
experimental colitis. J Pineal Res. 41:363–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li JH, Yu JP, Yu HG, et al: Melatonin
reduces inflammatory injury through inhibiting NF-kappaB activation
in rats with colitis. Mediators Inflamm. 2005.185–193. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nosál’ová V1, Zeman M, Cerná S, Navarová J
and Zakálová M: Protective effect of melatonin in acetic acid
induced colitis in rats. J Pineal Res. 42:364–370. 2007. View Article : Google Scholar
|
|
10
|
Akcan A, Kucuk C, Sozuer E, et al:
Melatonin reduces bacterial translocation and apoptosis in
trinitrobenzene sulphonic acid-induced colitis of rats. World J
Gastroenterol. 14:918–924. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stebelová K, Herichová I and Zeman M:
Diabetes induces changes in melatonin concentrations in peripheral
tissues of rat. Neuro Endocrinol Lett. 28:159–165. 2007.PubMed/NCBI
|
|
12
|
Cuzzocrea S, Mazzon E, Serraino I, et al:
Melatonin reduces dinitrobenzene sulfonic acid-induced colitis. J
Pineal Res. 30:1–12. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong WG, Mei Q, Yu JP, et al: Effects of
melatonin on the expression of iNOS and COX-2 in rat models of
colitis. World J Gastroenterol. 9:1307–1311. 2003.PubMed/NCBI
|
|
14
|
Tahan G, Gramignoli R, Marongiu F, et al:
Melatonin expresses powerful anti-inflammatory and antioxidant
activities resulting in complete improvement of acetic-acid-induced
colitis in rats. Dig Dis Sci. 56:715–720. 2011. View Article : Google Scholar
|
|
15
|
van Hulzen ZJ and Coenen AM: Effects of
paradoxical sleep deprivation on two-way avoidance acquisition.
Physiol Behav. 29:581–587. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee YD, Kim JY, Lee KH, et al: Melatonin
attenuates lipopoly-saccharide-induced acute lung inflammation in
sleep-deprived mice. J Pineal Res. 46:53–57. 2009. View Article : Google Scholar
|
|
17
|
Levenstein S, Prantera C, Varvo V, et al:
Stress and exacerbation in ulcerative colitis: a prospective study
of patients enrolled in remission. Am J Gastroenterol.
95:1213–1220. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Y, Preuss F, Turek FW, Jakate S and
Keshavarzian A: Sleep deprivation worsens inflammation and delays
recovery in a mouse model of colitis. Sleep Med. 10:597–603. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Swanson GR, Burgess HJ and Keshavarzian A:
Sleep disturbances and inflammatory bowel disease: a potential
trigger for disease flare? Expert Rev Clin Immunol. 7:29–36. 2011.
View Article : Google Scholar :
|
|
20
|
Boye B, Lundin KE, Jantschek G, et al:
INSPIRE study: does stress management improve the course of
inflammatory bowel disease and disease-specific quality of life in
distressed patients with ulcerative colitis or Crohn’s disease? A
randomized controlled trial. Inflamm Bowel Dis. 17:1863–1873. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lerner AB, Case JD, Lee TH and Mori W:
Isolation of melatonin, the pineal factor that lightens
melanocytes. J Am Chem Soc. 80:25871958. View Article : Google Scholar
|
|
22
|
Bubenik GA: Thirty four years since the
discovery of gastrointestinal melatonin. J Physiol Pharmacol.
59(Suppl 2): S33–S51. 2008.
|
|
23
|
Thor PJ, Krolczyk G, Gil K, Zurowski D and
Nowak L: Melatonin and serotonin effects on gastrointestinal
motility. J Physiol Pharmacol. 58(Suppl 6): S97–S103. 2007.
|
|
24
|
Chen CQ, Fichna J, Bashashati M, Li YY and
Storr M: Distribution, function and physiological role of melatonin
in the lower gut. World J Gastroenterol. 17:3888–3898. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Esposito E, Mazzon E, Riccardi L, et al:
Matrix metallopro-teinase-9 and metalloproteinase-2 activity and
expression is reduced by melatonin during experimental colitis. J
Pineal Res. 45:166–173. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Winiarska K, Fraczyk T, Malinska D, Drozak
J and Bryla J: Melatonin attenuates diabetes-induced oxidative
stress in rabbits. J Pineal Res. 40:168–176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mei Q, Yu JP, Xu JM, et al: Melatonin
reduces colon immunological injury in rats by regulating activity
of macrophages. Acta Pharmacol Sin. 23:882–886. 2002.PubMed/NCBI
|
|
28
|
Ranjbaran Z, Keefer L, Farhadi A, et al:
Impact of sleep disturbances in inflammatory bowel disease. J
Gastroenterol Hepatol. 22:1748–1753. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Keefer L, Stepanski EJ, Ranjbaran Z,
Benson LM and Keshavarzian A: An initial report of sleep
disturbance in inactive inflammatory bowel disease. J Gastroenterol
Hepatol. 2:409–416. 2006.
|
|
30
|
Bergmann BM, Gilliland MA, Balzano S,
Refetoff S and Rechtschaffen A: Sleep deprivation in the rat: XIX.
Effects of thyroxine administration Sleep. 18:317–324. 1995.
|
|
31
|
Trivedi PP and Jena GB: Melatonin reduces
ulcerative colitis-associated local and systemic damage in mice:
investigation on possible mechanisms. Dig Dis Sci. 58:3460–3474.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Westbrook AM, Wei B, Hacke K, et al: The
role of tumour necrosis factor-α and tumour necrosis factor
receptor signalling in inflammation-associated systemic
genotoxicity. Mutagenesis. 27:77–86. 2012. View Article : Google Scholar
|
|
33
|
Arthur JC, Perez-Chanona E, Mühlbauer M,
et al: Intestinal inflammation targets cancer-inducing activity of
the microbiota. Science. 338:120–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reyland ME: Protein kinase C isoforms:
Multi-functional regulators of cell life and death. Front Biosci
(Landmark Ed). 14:2386–2399. 2009. View
Article : Google Scholar
|
|
35
|
Means AR, VanBerkum MF, Bagchi I, Lu KP
and Rasmussen CD: Regulatory functions of calmodulin. Pharmacol
Ther. 50:255–270. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kankuri E, Asmawi MZ, Korpela R, Vapaatalo
H and Moilanen E: Induction of iNOS in a rat model of acute
colitis. Inflammation. 23:141–152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
You J, Nguyen AV, Albers CG, Lin F and
Holcombe RF: Wnt pathway-related gene expression in inflammatory
bowel disease. Dig Dis Sci. 53:1013–1019. 2008. View Article : Google Scholar
|
|
38
|
Du Q, Park KS, Guo Z, et al: Regulation of
human nitric oxide synthase 2 expression by Wnt beta-catenin
signaling. Cancer Res. 66:7024–7031. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pereira CP, Bachli EB and Schoedon G: The
wnt pathway: a macrophage effector molecule that triggers
inflammation. Curr Atheroscler Rep. 11:236–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Baert F, Vermeire S, Noman M, et al:
Management of ulcerative colitis and Crohn’s disease. Acta Clin
Belg. 59:304–314. 2004. View Article : Google Scholar
|
|
41
|
Malhotra S, Bhasin D, Shafiq N and Pandhi
P: Drug treatment of ulcerative colitis: unfractionated heparin,
low molecular weight heparins and beyond. Expert Opin Pharmacother.
5:329–334. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chojnacki C, Wisniewska-Jarosinska M,
Walecka-Kapica E, et al: Evaluation of melatonin effectiveness in
the adjuvant treatment of ulcerative colitis. J Physiol Pharmacol.
62:327–334. 2011.PubMed/NCBI
|
|
43
|
Rakhimova O: Use of melatonin in combined
treatment for inflammatory bowel diseases. Ter Arkh. 82:64–68.
2010.In Russian.
|
|
44
|
Motilva V, Garcia-Maurino S, Talero E and
Illanes M: New paradigms in chronic intestinal inflammation and
colon cancer: role of melatonin. J Pineal Res. 51:44–60. 2011.
View Article : Google Scholar : PubMed/NCBI
|
